November 20, 2019 – Millennium Health has been named by The Silicon Review as one of the 50 Most Trustworthy Companies of the Year for 2019. The Silicon Review is the world’s most trusted online and print community for business and technology professionals.
Testing for Fentanyl and Analogues May Help Prevent Deaths by Overdose
SAN DIEGO, Calif. – July 17, 2019 – Millennium Health, a leader in identifying and responding to illicit and prescription drug use trends, has expanded its urine drug test offering to include fentanyl analogues. Up to 10,000-fold more potent than morphine,¹ and often spiked into, or used concomitantly with heroin, cocaine or methamphetamine, these analogues pose a serious risk for overdose.Read More
Cross-Sectional Study by Millennium Health Demonstrates the Need to Educate the Public of Heightened Risk of Overdose
SAN DIEGO, Calif. – May 1, 2019 – A study published in JAMA Network Open reports that between January 2013 and September 2018, the presence of non-prescribed fentanyl among urine drug tests also positive for cocaine or methamphetamine rose 1850% and 798% respectively. This analysis provides the public with additional insight into trending increases in reported cocaine- and methamphetamine-related overdoses. Cocaine and methamphetamine related drug overdose deaths are rising sharply. These data suggest the increase may be related to the simultaneous presence of fentanyl, either added directly to the drug supply or used concomitantly.
A Five-Year Retrospective Analysis of Over Five Million Test Results
SAN DIEGO, Calif. – March 6, 2019 – Millennium Health, in close collaboration with independent clinical experts, has analyzed its proprietary database of millions of drug test results from the last five years to answer some of the most pressing questions associated with trends in medication use and substance abuse today.
Lukowiak provides strong molecular diagnostics experience and leadership to Millennium Health
SAN DIEGO, Calif. – February 27, 2018 – Millennium Health, a leading health solutions company, is pleased to announce the appointment of Andrew A. Lukowiak, Ph.D. as Chief Executive Officer (CEO) effective March 1, 2018. Dr. Lukowiak has nearly 20 years of management experience in molecular diagnostics and most recently served as the Chief Operating Officer (COO) and interim-CEO of a privately held precision medicine company, where he had been a part of the management team since 2013.
Patient Billing
(877) 451-7337
Monday-Friday 6:00AM-5:00PM PT
Corporate Headquarters
(877) 451-3534
